Brought to you by 
GSK gets cancer immunotherapeutics from MD Anderson
16 Nov 2021
Executive Summary
The University of Texas’ MD Anderson Cancer Center has licensed GlaxoSmithKline PLC exclusive global rights to develop and sell OX40-activating antibodies for cancer. NOTE: One of the antibody programs is known as GSK3174998.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK gets cancer immunotherapeutics from MD Anderson
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice